
I continue to thoroughly enjoy Steve Bell’s coverage of the HUGO platform trajectory and the broader discussion it has sparked around the future of soft-tissue robotics. It is encouraging to see the progress Medtronic and other large-format robotics players have made over the past 12 months. Momentum matters. Execution matters.
But framing matters even more.
That’s why the growing call-to-action from the masses for Medtronic to get Ligasure and ICG onto the arm of a robot is the standard chant of the large strategics that have been raised in them. At times, it feels like over-celebrating the King of the Prom at his 30-year high school reunion where the killer mullet has quietly turned into a sad comb-over. These were glory-day technologies. Certainly, important ones. Category-defining in their time. But nostalgia is not a strategy, it is a deathblow to an existing category leader.
Ligasure or ICG most definitely bring value. It’s that too much organizational energy may be poured into perfecting yesterday’s answers instead of building tomorrow’s questions and ultimate market-shifting opportunities. I hope Medtronic is not allocating disproportionate resources to retrofitting legacy heroes at the expense of creating an entirely new surgical sandbox, one that finally owns the game upstream from the device.
Because these conversations about the “criticality” of Ligasure and ICG are symptomatic of what put both Medtronic and Johnson & Johnson into the surgical robotics hole in the first place. They kept innovating but within the wrong frame.
Both organizations built best-in-class staplers, energy devices, sutures, and access tools. They optimized performance, reliability, and scale inside the same sandbox that had served them for decades. Meanwhile, Intuitive Surgical didn’t bother trying to build better versions of the same tools. Instead, it designed a new system upstream from the analog one: a digital system made up of robotics, software, visualization, data, training, and workflow. That system created long-term clinician lock-in and quietly reorganized the category.
Surgery didn’t disappear. It reorganized.
And when that happened, the former category leaders didn’t fail, instead they became device components inside someone else’s ecosystem. That outcome should permanently dispel the myth that category leadership and technical excellence are enduring moats. They are not.
Putting Ligasure and ICG onto a surgical robot is, by definition, iterative development. It improves what exists. It does not redefine the category. The next true step-change in digital surgery is far more likely to come from image-guided surgery and visualization-centric platforms because that is where the highest density of data in the operating room already lives, and where even more will accumulate tomorrow.
ICG is useful. Ligasure is proven. But both represent where the hockey puck was. And notably, neither Medtronic nor Johnson & Johnson currently appear to own a substantial native visualization platform capable of anchoring that next wave. That absence matters, because value is no longer concentrated in the device itself. It is migrating rapidly into data, analytics, imaging, protocols, and workflows that sit upstream of the instrument.
When will industry leadership fully internalize that shift?
This is where ambidextrous leadership becomes more than a buzzword. Leaders must simultaneously defend today’s revenue engines while legitimizing a future engine that looks inefficient, uncertain, and uncomfortable by comparison. That future cannot be governed by the same metrics, timelines, or success criteria as the core business or it will never survive internal competition.
The minimally invasive surgery sector is already showing the consequences of hesitation. Pricing power is eroding in real time. Differentiation is narrowing. Strategic control of operating rooms across hospitals, ASCs, and office-based settings is slipping away from device manufacturers and toward platform owners.
And this pattern will not stop with soft-tissue robotics.
Interventional companies, take note. You are next.
What happened in MIS will make its way to the cath lab, the EP suite, and beyond. The sequence is always the same: a company leads a category until another organization builds a platform that provides data, analytics, imaging, protocols, and workflow around the device. Market leadership doesn’t vanish overnight it is gradually reallocated.
Until one day it’s gone.
This is the trap large market leaders fall into more than anyone else. Their success becomes self-reinforcing. Governance, incentives, and culture all reward protecting what works today. Over time, that success becomes a prison unless leadership consciously breaks out of it.
Categories do not disappear. They reorganize.
And leadership is rarely taken by force. More often, it is fumbled away one rational, incremental decision at a time.
It is always gradual.
Until it is sudden.